Home » Stocks » ASRT

Assertio Therapeutics, Inc. (ASRT)

Stock Price: $0.492 USD 0.027 (5.83%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $0.494 +0.002 (0.35%) May 14, 7:56 PM
Market Cap 80.85M
Revenue (ttm) 112.20M
Net Income (ttm) -64.83M
Shares Out 173.79M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE 4.90
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $0.492
Previous Close $0.465
Change ($) 0.027
Change (%) 5.83%
Day's Open 0.470
Day's Range 0.470 - 0.495
Day's Volume 2,701,891
52-Week Range 0.330 - 1.450

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |...

Other stocks mentioned: ACST, TTOO
1 week ago - PennyStocks

Reported Net Product Sales of $26.4 Million, Compared to Prior Year Pro-Forma Net Products Sales of $28.3 Million

1 week ago - GlobeNewsWire

Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, and Continuous Online Physician Care Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, a...

1 week ago - GlobeNewsWire

LAKE FOREST, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Th...

3 weeks ago - GlobeNewsWire

It's never a dull day on the Reddit Penny Stocks subreddit and we're checking in to see what's being talked about the most today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared...

Other stocks mentioned: INPX, NAKD, TMBR, ZOM
4 weeks ago - InvestorPlace

Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with Guidance

2 months ago - GlobeNewsWire

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

LAKE FOREST, Ill., March 01, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that Dan Peisert, President and Chief Executive Officer of Asse...

2 months ago - GlobeNewsWire

LAKE FOREST, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2020 financial...

2 months ago - GlobeNewsWire

LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of com...

3 months ago - GlobeNewsWire

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain...

3 months ago - GlobeNewsWire

LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of com...

3 months ago - GlobeNewsWire

Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase 22.6 million common shares at $0.62 per share in a registered direc...

3 months ago - Benzinga

LAKE FOREST, Ill., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain...

3 months ago - GlobeNewsWire

LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Thera...

3 months ago - GlobeNewsWire

Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing

4 months ago - GlobeNewsWire

LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief exec...

6 months ago - GlobeNewsWire

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will p...

8 months ago - GlobeNewsWire

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07.

9 months ago - Benzinga

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financ...

9 months ago - GlobeNewsWire

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt --

1 year ago - GlobeNewsWire

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender off...

1 year ago - GlobeNewsWire

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1

1 year ago - GlobeNewsWire

LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) ...

1 year ago - GlobeNewsWire

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

1 year ago - Zacks Investment Research

Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance

1 year ago - Seeking Alpha

Also Announces its Senior Secured Debt Has Been Repaid in Full Also Announces its Senior Secured Debt Has Been Repaid in Full

1 year ago - GlobeNewsWire

Assertio (ASRT) closed at $1.35 in the latest trading session, marking a -0.74% move from the prior day.

1 year ago - Zacks Investment Research

Company Intends to Use Cash Proceeds to Retire its Outstanding Debt

1 year ago - GlobeNewsWire

Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.

1 year ago - Zacks Investment Research

Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.

1 year ago - Zacks Investment Research

Is (ASRT) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
1 year ago - Zacks Investment Research

LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement (“Agree...

1 year ago - GlobeNewsWire

About ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of mi... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Nov 5, 1997
Stock Exchange
NASDAQ
Ticker Symbol
ASRT
Full Company Profile

Financial Performance

In 2020, ASRT's revenue was $106.28 million, a decrease of -53.69% compared to the previous year's $229.50 million. Losses were -$28.14 million, -87.04% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 1.55, which is an increase of 214.85% from the latest price.

Price Target
$1.55
(214.85% upside)
Analyst Consensus: Buy